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Abstract
Primary primitive neuroectodermal tumor (PNET) of the female genital tract is rare, and its proper 
classification remains unclear. The clinical, histologic, and immunophenotypic features as well as 
EWSR1 rearrangement status of 19 gynecologic PNETs, including 10 ovarian, 8 uterine, and 1 
vulvar tumors, are herein reported. Patient age ranged from 12 to 68 years, with a median age of 
20 and 51 years among those with ovarian and uterine PNETs, respectively. Morphologic features 
of central nervous system (CNS) tumors were seen in 15 PNETs, including 9 medulloblastomas, 3 
ependymomas, 2 medulloepitheliomas, and 1 glioblastoma, consistent with central PNET. The 
remaining 4 PNETs were composed entirely of undifferentiated small round blue cells and were 
classified as Ewing sarcoma/peripheral PNET. Eight PNETs were associated with another tumor 
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type, including 5 ovarian mature cystic teratomas, 2 endometrial low-grade endometrioid 
carcinomas and a uterine carcinosarcoma. By immunohistochemistry, 17 PNETs expressed at least 
1 marker of neuronal differentiation, including synaptophysin, NSE, CD56, S100, and 
chromogranin in 10, 8, 14, 8, and 1 tumors, respectively. GFAP was positive in 4 PNETs, all of 
which were of central type. Membranous CD99 and nuclear Fli-1 staining was seen in 10 and 16 
tumors, respectively, and concurrent expression of both markers was seen in both central and 
Ewing sarcoma/peripheral PNETs. All tumors expressed vimentin; while keratin cocktail 
(CAM5.2, AE1/AE3) staining was only focally present in 4 PNETs. Fluorescence in situ 
hybridization was successful in all cases and confirmed EWSR1 rearrangement in 2 of 4 tumors 
demonstrating morphologic features of Ewing sarcoma/peripheral PNET and concurrent CD99 
and Fli-1 expression. In conclusion, central and Ewing sarcoma/peripheral PNETs may be 
encountered in the female genital tract with central PNETs being more common. Central PNETs 
show a spectrum of morphologic features that overlaps with CNS tumors but lack EWSR1 
rearrangements. GFAP expression supports a morphologic impression of central PNET and is 
absent in Ewing sarcoma/peripheral PNET. Ewing sarcoma/peripheral PNETs lack morphologic 
features of CNS tumors.
INTRODUCTION
Primitive neuroectodermal tumor (PNET) is a term devised to represent a biologically 
aggressive, poorly differentiated malignant neoplasm that demonstrates cellular 
differentiation that recapitulates cell types of the central nervous system (CNS). The entity 
has been grouped into 2 major categories, namely, those that mimic neoplasms of the CNS, 
i.e. central PNET, and those composed of small round cells with or without rosettes known 
as extraosseous Ewing sarcoma or peripheral PNET. PNET may arise in many anatomic 
regions of the body, including the gynecological tract. Gynecologic PNETs have been 
reported in the ovary (1–7), broad ligament (1, 8), uterine corpus (1, 9–18), uterine cervix (1, 
19–25), vagina (26–32), and vulva (1, 26, 31, 33–39); to date, none have been reported to 
have arisen in the fallopian tube. PNETs of the ovary and uterus are frequently associated 
with another tumor type (2, 4–6, 10, 11, 18), although many, including those arising 
elsewhere, occur in pure form (1, 3, 4, 7, 9, 10, 13–17, 19–37, 39–41). Together, they 
represent a peculiar group of rare neoplasms that show varying degrees of neuroectodermal 
differentiation and remain poorly understood when compared to their bone and soft tissue 
counterparts (42) and tumors that until recently were classified as PNETs of the CNS (43).
Some gynecologic PNETs harbor EWSR1 rearrangements and thus are considered of the 
peripheral type or Ewing sarcoma, a neoplasm with a wide morphologic spectrum that is 
defined by translocations producing fusion of EWSR1 to various members of the ETS 
family of transcription factors (42). PNETs arising in the female genital tract that lack 
EWSR1 rearrangements and show readily recognizable neuroectodermal differentiation 
morphologically reminiscent of CNS tumors are likely histogenetically separate from Ewing 
sarcoma/peripheral PNETs (4, 10, 13). However, distinction of central PNETs from Ewing 
sarcoma/peripheral PNETs remains a significant challenge due to overlapping histologic and 
immunophenotypic features seen in both types and because the literature contains the term 
Ewing sarcoma/peripheral PNET that has been used loosely and is largely limited to 
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descriptive case reports and small case series in which the status of EWSR1 rearrangement 
is not known.
A comprehensive classification of gynecologic PNETs incorporating morphologic, 
immunohistochemical, and molecular genetic features is critical to ensure accurate 
diagnosis, prognosis, and treatment for patients with these rare tumors. In this study, we 
evaluated clinical, histologic, and immunohistochemical features as well as the EWSR1 
rearrangement status of 19 gynecologic PNETs arising in various sites to determine whether 
these neoplasms are of the central type or belong to the Ewing family of tumors in order to 
provide refined criteria for accurate diagnosis.
MATERIALS AND METHODS
Case selection and classification
Nineteen gynecologic PNETs diagnosed between 1989 and 2007 were collected from the 
surgical pathology files of 6 institutions (Massachusetts General Hospital, McMaster 
Hospital, Saitama International Medical Center, University of Sassari, Prefectural Miyazaki 
Hospital, and Leipzig University) and the consultation files of E.O. and the late Dr. Robert 
E. Scully. Six cases were previously reported (4, 9). Pathology reports and hematoxylin-and-
eosin (H&E) stained slides were reviewed by 4 pathologists (S.K., M.S., A.E.R, and E.O.) to 
confirm the diagnosis of PNET and further categorize the tumors as either central or Ewing 
sarcoma/peripheral PNET based on morphologic features of neuroectodermal 
differentiation. A tumor was designated as central PNET if it exhibited sheets of poorly 
differentiated small round blue cells and one of the following features: 1) neuronal 
differentiation with pale islands of neuropil, 2) glial features with astrocytic or ependymal 
differentiation with true ependymal rosettes or vascular pseudorosettes, and 3) architectural 
features of a primitive neural tube characterized by pseudostratified neuroepithelium with 
tubular spaces, neuroblastic rosettes, or tubular multilayered rosettes. Tumors classified as 
central PNET were further subcategorized by the type of divergent differentiation along 
neuronal, astrocytic, and ependymal lines. The presence of microvascular proliferation and 
pseudopalisading necrosis was also recorded. Tumors were classified as Ewing sarcoma/
peripheral PNET if composed of sheets of undifferentiated small round blue cells with no 
morphologic features suggestive of central PNET. In all cases, the association with another 
tumor type was noted. Available clinical information, including presentation, stage, therapy, 
and follow-up, were obtained.
Immunohistochemistry
Immunohistochemistry was performed on 5-μm formalin-fixed paraffin-embedded (FFPE) 
tumoral tissue sections mounted on charged glass slides in 18 cases for which sufficient 
tumoral tissue was available. Antibodies to Fli-1 (1:160 dilution, Santa Cruz Biotechnology, 
CA), CD99 (1:100 dilution; Novocastra, CA), synaptophysin (predilute, Ventana Medical 
Systems, Inc., AZ) , chromogranin A (predilute, Ventana Medical Systems, AZ), CD10 
(predilute, Ventana Medical Systems, AZ), CD56 (predilute, Cell Marque, CA), glial 
fibrillary acidic protein (GFAP) (predilute, Ventana Medical Systems, AZ), neuron specific 
enolase (NSE) (1:150 dilution, Dako, CA; antigen retrieval not applied), S100 (predilute, 
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Ventana Medical Systems, AZ), vimentin (predilute, Ventana Medical Systems, AZ), and 
cytokeratins CAM5.2 (1:80 dilution, Becton & Dickinson, CA) and AE1/AE3, (1:160, 
Signet Laboratories, MA; Protease1 was used for antigen retrieval), were used for 
immunohistochemical staining with appropriate controls. Staining was done on a 
BenchMark XT automated tissue staining system (Ventana Medical Systems, AZ) using 
validated protocols as described previously (44). Endogenous peroxidase activity was 
blocked by H2O2 before antibody incubation. A combination of ethylenediaminetetraacetic 
acid and boric acid in Tris buffer (Mild to Standard CC1 reagent; Ventana Medical Systems, 
AZ) was applied to the tissue sections for antigen retrieval prior to primary antibody 
incubation. Tissue sections were washed and incubated with primary antibodies, followed by 
incubation with UltraView HRP-conjugated multimer antibody reagent (Igs; Ventana 
Medical Systems, AZ). Antigen detection was performed using UltraView diaminobenzidine 
chromogen (Ventana Medical Systems, AZ). Tissue sections were counterstained with 
hematoxylin.
Fluorescence in situ hybridization (FISH)
Dual color FISH was performed to identify the presence of an EWSR1 rearrangement using 
an EWSR1 break-apart probe (Vysis LSI® EWS (9q22) Dual Color, Break Apart 
Rearrangement Probe). Briefly, 5-μm sections of FFPE tumoral tissue from all 19 cases were 
mounted on charged slides. A serial H&E-stained slide was used to identify tumoral tissue. 
Unstained slides were deparaffinized, subjected to 2 25-minute rounds of pepsin digestion at 
37 °C, dehydrated in 70%, 95%, and 100% ethanol for 2 minutes each, and air dried. Probe 
(3 μL) was applied to each slide, followed by denaturation of the probe and target at 80 °C 
for 5 minutes and overnight hybridization at 37 °C. Slides were washed in 2× standard 
sodium citrate for 2 minutes twice at 37 °C. Nuclei were counterstained with DAPI. Images 
were acquired with an Olympus BX61 fluorescent microscope equipped with a charge-
coupled device camera and analyzed with Cytovision software (Genetix, San Jose, CA). For 
each slide, 50 cells were scored. EWSR1 rearrangement was reported as present if >15% of 
the tumor cells showed split signals defined as separation of signals by more than 2 signal 
diameters.
RESULTS
Clinical features
Our cohort consisted of 10 ovarian, 8 uterine, and 1 vulvar PNET (Table 1). Patient age 
ranged from 12 to 68 (median, 34) years. The median age of patients with ovarian and 
uterine tumors was 20 and 51 years, respectively, while the vulvar PNET occurred in a 65 
year old. Central PNET was found in patients with age ranging from 12 to 68 (median, 34) 
years. Patient age was known in only 2 patients with Ewing sarcoma/peripheral PNET being 
26 and 65 years, respectively. Additional clinical history was available in 13 patients in 
whom vaginal bleeding and pelvic mass detected on physical examination or imaging were 
the most common presentations in 5 and 6 patients, respectively. Disseminated 
intraabdominal disease, ascites, and back pain were less common presentations of patients 
with ovarian PNET, while the patient with vulvar PNET complained of a rapidly growing 
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mass. Clinical data was limited in a subset of patients due to individual contributions from 
different institutions.
Tumor stage was highly variable among patients with ovarian and uterine PNETs (Table 1). 
Among 9 patients with ovarian PNET and available tumor staging data, 4 had stage I 
disease; however, 3 and 1 patients had stage III and IV disease, respectively. The majority of 
patients with uterine PNET had high-stage disease, including 5 stage III and 1 stage IV 
tumors; only 1 patient had a uterus-confined PNET. The single patient with a vulvar PNET 
had a stage I tumor. Among patients with central PNET, 4 had stage I or II disease (all 
ovarian), while 8 and 2 had stage III (3 ovarian, 5 uterine) and stage IV (1 ovarian, 1 uterine) 
tumors. Three of 4 patients with Ewing sarcoma/peripheral PNET had stage I disease (1 
ovarian, 1 uterine, 1 vulvar). Staging information was not available for 1 patient with Ewing 
sarcoma/peripheral PNET.
Treatment among patients also varied widely (Table 1). Among 8 patients with ovarian 
PNETs and available treatment history, 6 underwent unilateral salpingo-oophorectomy, 1 of 
whom also had a contralateral salpingectomy and another had lymph node dissection and 
staging omental and peritoneal biopsies; and yet another had adjuvant radiation therapy. 
Among the 2 other patients, 1 underwent bilateral salpingo-oophorectomy and omentectomy 
followed by chemotherapy, while another had hysterectomy and bilateral salpingo-
oophorectomy, lymph node dissection, and omental biopsies. Eight patients with uterine 
PNETs underwent hysterectomy with bilateral salpingo-oophorectomy, 2 of them with 
lymph node dissection. Two patients received adjuvant chemotherapy. The patient with a 
vulvar PNET underwent a wide local excision.
Outcome data was limited to 10 patients (Table 1). Among the 6 patients with ovarian 
PNETs, 5, including those with stage III and IV tumors, were alive with no evidence of 
disease at last followup (range, 12–36 months); however, 1 patient with a stage III tumor 
died of disease 3 months after her initial presentation. Clinical follow-up data was available 
in 4 patients with uterine PNET. Two patients with stage III tumors were alive without 
evidence of disease, while 2 patients with stage III and stage IV tumors died of disease 6 and 
12 months after initial presentation, respectively.
Pathologic Features
Gross Findings—Gross features were available in 8 ovarian, 4 uterine, and vulvar PNETs. 
The ovarian tumors were all unilateral, except 1. Tumor size ranged from 5.5 to 55.0 
(median, 18.0) cm. One tumor was entirely solid, and 7 were solid and cystic (6 multilocular 
and 1 unilocular). Teratomatous elements, including waxy sebaceous or gelatinous material, 
hair, bone, or teeth, were evident in 4 of the cystic tumors; fatty nodularity was seen in 2. 
The solid component had a white, tan, or pink, sometimes hemorrhagic cut surface, and 
appeared nodular in 2 neoplasms. The uterine tumors ranged in size from 5.3 to 20.0 
(median, 5.7) cm and were pedunculated to polypoid, fleshy and at least focally hemorrhagic 
masses protruding into the endometrial cavity; 1 was transmurally invasive to involve the 
serosa and had a pale, lobulated, and gelatinous cut surface. The vulvar tumor measured 1.5 
cm in greatest dimension and was well-circumscribed.
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Microscopic Findings—All 19 PNETs were composed of sheets or nodules of densely 
packed primitive cells with small- to medium-sized, round to ovoid nuclei, 1 to multiple 
small nucleoli, and scant cytoplasm; mitoses were always numerous (>10/10 high power 
fields). Fifteen (77.8%) tumors, including 8 arising in the ovary and 7 arising in the uterus, 
demonstrated histologic evidence of CNS differentiation in addition to a predominant small 
round blue cell component and were classified as central PNET (Table 2). Neuroblastic 
differentiation was seen in 11, including 9 tumors composed of nodules and round pale 
islands of neuropil with low cellularity displaying cells with larger nuclei and occasional 
nucleoli, consistent with medulloblastoma (Figure 1A–D); more differentiated areas with 
finely granular eosinophilic neuropil (Figure 1A–C) were often found adjacent to the 
undifferentiated areas (Figure 1B, D). The other 2 tumors demonstrating neuroblastic 
differentiation had morphologic features of medulloepithelioma defined by primitive small 
round blue cells arranged in multilayered tubules and rosettes with mitoses present near the 
lumen (Figure 2A, B). Four tumors showed distinct glial differentiation with foci of dense 
eosinophilic fibrillarity often neighboring primitive undifferentiated small round blue cell 
areas. Ependymal differentiation including vascular pseudorosettes were seen in 3 of these 
tumors, but true ependymal rosettes were exceedingly rare. One tumor showed 
predominantly astrocytic differentiation and was composed of large cells with abundant pink 
cytoplasm, large nuclei, and prominent nucleoli accompanied by pseudopalisading necrosis 
(Figure 2C) and microvascular proliferation (Figure 2D), consistent with glioblastoma. 
Necrosis was present in 11 neoplasms classified as central PNET; however, only tumors 
demonstrating glial differentiation showed serpentine foci of pseudopalisading necrosis. 
Tumors with features of neuronal differentiation, including medulloblastoma and 
medulloepithelioma, showed large geographic areas of necrosis with an abrupt border 
adjacent to viable tumor and without pseudopalisading of nuclei. Central PNETs with glial 
differentiation showed glomeruloid microvascular proliferation which was most prominent 
in the case demonstrating features of glioblastoma. Eight of the 15 central PNETs were 
associated with another tumor, including 5 mature cystic teratomas of the ovary, 2 
endometrial low-grade endometrioid carcinomas, and a uterine carcinosarcoma.
Four (22.2%) tumors in our cohort showed no morphologic evidence of CNS differentiation 
and were classified as Ewing sarcoma/peripheral PNET (Figure 3A). These included 2 
tumors arising in the ovary, 1 in the uterus, and 1 in the vulva. The single uterine Ewing 
sarcoma/peripheral PNET demonstrated permeative/destructive invasion into the 
myometrium, while the vulvar Ewing sarcoma/peripheral PNET was well-circumscribed. 
Microvascular proliferation was absent. Necrosis was seen in only 1 Ewing sarcoma/
peripheral PNET arising in the ovary and was extensive. None of the Ewing sarcoma/
peripheral PNETs were found associated with another tumor type.
Immunohistochemical features—Immunohistochemical findings are summarized in 
Table 2. All tumors tested were strongly positive for vimentin. Both central and Ewing 
sarcoma/peripheral PNETs showed strong diffuse expression of various neuronal markers. 
Synaptophysin, chromogranin, CD56, NSE, and S100 were expressed in 64.3%, 7.1%, 
85.7%, 42.9%, and 42.9% of CNS-like PNETs, compared to 50.0%, 0%, 75.0%, 50.0%, and 
75.0% of Ewing sarcoma/peripheral PNETs, respectively. Synaptophysin highlighted pale 
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islands of neuropil in central PNETs (Figure 4A); however in some tumors, only scattered 
cells expressed this marker strongly. GFAP was strongly expressed in 3 central PNETs, 
including 2 with ependymal differentiation and 1 showing features of glioblastoma. In 
addition to these 3 cases, 1 central PNET with medulloblastoma showed scattered GFAP-
positive cells demonstrating astrocytic features (Figure 4B). GFAP expression was absent in 
all Ewing sarcoma/peripheral PNETs. Neurofilament was negative in both central and Ewing 
sarcoma/peripheral PNETs. Membranous CD99 staining was seen in half of central PNETs, 
of which 5 showed diffuse and 2 focal positivity, and all 4 PNETs, of which half displayed 
diffuse and half focal staining. Nuclear Fli-1 positivity was observed 85.7% of central 
PNETs and was diffuse in half and focal in the remainder, while it was diffusely expressed 
in all 4 Ewing sarcoma/peripheral PNETs. Two central PNETs showed concurrent CD99 and 
Fli-1 expression, but only 1 had concurrent strong and diffuse staining of both markers 
(Figure 4C, D). In contrast, concurrent CD99 and Fli-1 expression was seen in all 4 Ewing 
sarcoma/peripheral PNETs (Figure 3B, C). CD10 was not expressed in any central PNETs 
with glial differentiation, but was noted in 4 central PNETs with neuronal differentiation (3 
medulloblastomas and 1 medulloepithelioma) as well as 2 Ewing sarcoma/peripheral 
PNETs. Cytokeratin cocktail (CAM5.2 and AE1/AE3) was only focally positive in 1 Ewing 
sarcoma/peripheral and 3 central PNETs.
FISH
FISH analysis was successful in all 19 tumors and detected EWSR1 rearrangement in only 2 
(11.1%) cases in the vulva and uterus which both showed morphologic features consistent 
with Ewing sarcoma/peripheral PNET (Figure 3D). The other 2 ovarian tumors classified as 
Ewing sarcoma/peripheral PNET based on diffuse and strong membranous CD99 and 
nuclear Fli-1 expression did not show evidence of EWSR1 rearrangement by FISH. All 
central PNETs were negative for EWSR1 rearrangement.
DISCUSSION
Based on the findings from our study, the vast majority of gynecologic PNETs was of the 
central type and lacked EWSR1 rearrangement, while a minority represented Ewing 
sarcoma/peripheral type PNET in which EWSR1 rearrangement could be confirmed in two 
tumors. All central PNETs displayed at least focally morphologic features akin to those seen 
in CNS tumors and could be further classified into those exhibiting neuroblastic (i.e. 
medulloblastoma and medulloepithelioma) or glial differentiation (i.e. ependymoma and 
glioblastoma) by architectural growth patterns. Tumors that were composed entirely of 
sheets of primitive small round blue cells and showed both membranous CD99 and nuclear 
Fli-1 expression, but absence of GFAP staining by immunohistochemistry were more likely 
to harbor an EWSR1 rearrangement detectable by FISH, consistent with Ewing sarcoma/
peripheral PNET. The association with another tumor type was seen in approximately 50% 
of central PNETs, but not in Ewing sarcoma/peripheral PNETs. A combination of detailed 
morphologic assessment, panel of immunohistochemical stains, and EWSR1 FISH were 
essential in distinguishing central and Ewing sarcoma/peripheral types of gynecologic 
PNET.
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Our series joins 2 others as the largest studies of gynecologic PNETs arising in the ovary 
and uterus to date (4, 10). Based on our study and several others with well-annotated 
microscopic descriptions of tumor morphology and documentation of EWSR1 
rearrangement status, central PNETs appear to arise only in the ovary and uterine corpus (3, 
4, 7, 10, 13, 18). Ewing sarcoma/peripheral PNETs may also be encountered at these 2 sites 
(3, 7); however, findings from our study and few others (4, 10, 13) suggest that central 
PNETs predominate in the ovary and uterine corpus either alone or association with another 
tumor type, particularly an ovarian teratoma or a uterine carcinoma, carcinosarcoma, or 
sarcoma (2, 4–6, 9–12, 18). Interestingly, regardless of whether the tumor is central or 
peripheral type, patients with ovarian PNETs tend to be of reproductive age (median, 23 
years) (1, 3–7, 45) compared to those with uterine PNETs who are typically postmenopausal 
(median, 57 years) (1, 9–18, 40, 41). Among the 14 PNETs with known EWSR1 
rearrangement status reported in the cervix, vagina, and vulva (26, 30, 31, 34, 36–38), 
approximately 87%, including our single vulvar tumor, are Ewing sarcoma/peripheral 
PNETs confirmed by FISH or RT-PCR. None of the PNETs occurring at these sites, 
including the present case, were found associated with another neoplasm (1, 26–39). While 
our patient with a vulvar Ewing sarcoma/peripheral PNET was postmenopausal, patients 
with Ewing sarcoma/peripheral PNETs arising in the cervix, vagina, and vulva tend to be of 
reproductive age (median, 35, 34, and 21 years, respectively) (26, 30, 31, 34, 36–38).
Despite the awareness that central and Ewing sarcoma/peripheral PNETs exist in the female 
genital tract, their distinction is only infrequently discussed in the published literature (5, 11, 
13–15, 20, 24, 35). In many studies without molecular genetic analysis, the diagnosis of 
PNET particularly of the peripheral type was rendered based on the presence of CD99 
positivity in the setting of a predominately small round blue cell tumor with or without 
rosettes. The extent and location of CD99 staining was variably described, and tumors with 
only focal membranous or even cytoplasmic CD99 staining was considered supportive 
evidence of central type PNET in some studies (10, 15), while absence of CD99 staining 
was considered diagnostic of central PNET in others (2). It has also been suggested that 
PNETs without morphologic evidence of CNS differentiation and no detectable EWSR1 
rearrangement be classified as central PNETs (10). Whether some reports lacking 
confirmation of EWSR1 rearrangement truly represent Ewing sarcoma/peripheral PNET is 
subject to debate. Rare tumors that have morphologic and immunophenotypic features of 
Ewing sarcoma/peripheral PNET, but lack EWSR1 rearrangement may harbor less common 
alterations affecting FUS, BCOR, CCNB3, CIC, or DUX4 reported in the Ewing family of 
tumors involving the soft tissues and skeleton (46–49). A small portion of published 
gynecologic PNETs without molecular genetic analysis may in fact represent other more 
common entities in the differential diagnosis, including FIGO grade 3 endometrioid 
adenocarcinoma and undifferentiated or de-differentiated carcinoma based on the reported 
morphologic features and immunophenotype. Absence of EWSR1 rearrangement in our 2 
tumors initially classified as Ewing sarcoma/peripheral PNET prompted re-review of the 
morphologic and immunohistochemical findings. However, this diagnosis remained 
unchanged based on concurrent strong and diffuse membranous CD99 and nuclear Fli-1 
expression along with the extent of neuroendocrine marker staining (>10% of the overall 
tumor) exceeding what is typically seen in undifferentiated and de-differentiated carcinomas 
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(50). It is possible that these 2 tumors harbor genetic abnormalities other than rearrangement 
of EWSR1.
The distinction between central and peripheral types of gynecologic PNET likely has 
important clinical implications. Presence of an EWSR1 rearrangement in gynecologic 
PNETs may allow patients with Ewing sarcoma/peripheral PNET to be treated with 
therapeutic regimens used for the Ewing family of tumors in which a combination of surgery 
and/or radiation and multiagent systemic chemotherapy result in a 70% 5-year survival rate 
for localized disease (51, 52). Identification of central PNET and subclassification by 
neuronal, astrocytic, and ependymal lines of differentiation may also be helpful in 
identifying possible treatment modalities typically used for primary CNS tumors that may 
offer similar clinical benefit to patients with gynecologic central PNETs (53–55). A large 
number of CNS tumors classified as PNETs based solely on morphology and 
immunohistochemistry were recently found to display genome-wide DNA methylation 
profiles identical to other well-defined CNS tumor entities (43). True CNS PNETs were re-
classified according to underlying genetic aberrations into 4 new molecular entities 
including CNS neuroblastoma with FOXR2 activation, CNS Ewing sarcoma family tumor 
with CIC alteration, CNS high-grade neuroepithelial tumor with MN1 alteration, and CNS 
high-grade neuroepithelial tumor with BCOR alteration (43). Epigenetic profiling of central 
PNETs arising in the female genital tract, particularly in the ovary and uterus where central 
PNETs tend to be encountered, is a worthwhile endeavor and may enable more accurate 
diagnosis and therapeutic strategies for patients affected by this rare tumor type. Clinical 
data is limited in our cohort as well as in published studies, and differences in tumor 
behavior between central and Ewing sarcoma/peripheral PNETs arising in the female genital 
tract remains unknown.
The pathogenesis of gynecologic PNETs is unclear, and mechanisms of tumor development 
are likely dependent on primary site and association with another tumor type. The 
identification of teratoma in a significant minority of ovarian PNETs based on our study and 
others (2, 4–6) suggests germ cell derivation in at least a subset of tumors arising at this site. 
There have been rare reports of teratomas (45, 56–60) arising in the uterus, and while it is 
conceivable that teratoma may be a source of uterine PNETs as it is in the ovary, teratoma 
has not been found in association with PNET in the uterus (1, 9–25, 40, 41). The 
identification of benign glial tissue (61–63) in the uterus which may result from implantation 
of aborted fetal tissue (63), represents another possible source of both uterine gliomas (64, 
65) and PNETs. However, evolution from a Müllerian primary serves as a more likely 
explanation in the development of some uterine PNETs based on the not infrequent 
association with an endometrial carcinoma, carcinosarcoma, adenosarcoma, or pure sarcoma 
seen among mainly postmenopausal women in our study and in others (9–12, 18). Ectopic 
migration of neuroblasts from the neural crest during fetal development (9, 64) may be yet 
another hypothesis in the development of gynecologic PNETs in general, but does not 
explain the particular propensity for PNETs to develop in the female reproductive tract 
compared to the urinary or male genital tracts. The predominance of EWSR1-rearranged 
Ewing sarcoma/peripheral PNETs found in the cervix (19, 21, 22), vagina (26, 30, 31), and 
vulva (26, 31, 34, 36–38) suggests a developmental pathway at these sites similar to those 
arising in the soft tissues.
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PNET should be considered in the differential diagnosis of any small round blue cell tumor 
involving the female genital tract and confirmed as central or peripheral type by a 
combination of morphologic assessment, immunohistochemical analysis. PNETs may be 
encountered in pure form in most gynecologic sites, but may be associated with another 
histologic subtype in the ovary and uterus. A fibrillary background and/or rosette-like 
structures should raise suspicion for PNET and prompt the use of a panel of 
immunohistochemical stains, including cytokeratin, GFAP, neuronal markers, CD99, and 
Fli-1. These morphologic features alone are not diagnostic of central PNET and may also be 
seen in Ewing sarcoma/peripheral PNET, unless histologic evidence of neuronal or glial 
differentiation or architectural features of primitive neural tube is present. While neuronal 
markers are expressed in both central and Ewing sarcoma/peripheral PNETs, GFAP 
highlights glial differentiation that is seen only in the former. Cytokeratin expression is 
usually negative, but may be weak and focal in rare PNETs of both types; strong and more 
than focal cytokeratin staining should prompt reconsideration of other entities in the 
differential diagnosis. CD99 is highly sensitive in recognizing Ewing sarcoma/peripheral 
PNET, but is non-specific and should not be used alone. Strong and diffuse concurrent 
expression of CD99 and Fli-1 is characteristic of Ewing sarcoma/peripheral PNET in our 
study and should prompt confirmatory molecular genetic studies. Based on our study and 
one other (10), CD99 staining may be absent in central PNETs. However, all published 
gynecologic Ewing sarcoma/peripheral PNETs and our 2 tumors that harbor EWSR1 
rearrangement were CD99-positive (3, 7, 18, 19, 21, 22, 26, 31, 34, 36–38); thus, absent 
CD99 staining should prompt reconsideration of the diagnosis of Ewing sarcoma/peripheral 
PNET in the setting of a small round blue cell tumor.
Two entities should be considered in the differential diagnosis of PNET particularly when 
involving the ovary in women of reproductive age. The more common consideration is a 
grade 2 or 3 immature teratoma given the significant extent of neuroepithelial differentiation 
in both tumor types and the frequent association of PNET with teratoma. High grade 
immature teratomas often show a wider spectrum of neuroepithelial differentiation 
compared to PNETs which typically differentiate along only 1 or 2 cell lines (4). Immature 
teratomas also exhibit an admixture of endodermal, mesodermal, and ectodermal tissues 
which in PNETs, are overgrown by a confluent mass of neuroectodermal elements (4). 
Albeit rare, small cell carcinoma of hypercalcemic type should also be considered in the 
differential diagnosis of an ovarian small round blue cell tumor in a young patient. While 
small cell carcinoma of hypercalcemic type consists of sheets of small round blue cells that 
may stain for neuroendocrine markers similar to PNET, there are usually at least focal 
follicle formation and less frequently minor foci of mucinous epithelium; variable nuclear 
WT1, EMA and cytokeratin expression; and loss of BRG1 and BRM expression that are 
distinctive from PNET (66–68).
The differential diagnosis broadens in the setting of a uterine or ovarian tumor in the peri- 
and postmenopausal age groups. Undifferentiated carcinoma shares considerable 
morphologic and immunohistochemical overlap with PNET as both are often composed of 
sheets of monotonous, often dyshesive cells and show little if any immunoexpression of 
epithelial markers and may exhibit staining of various neuroendocrine markers. However, 
the extent of staining for neuroendocrine markers is more extensive in PNET than that 
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acceptable for undifferentiated carcinoma (50). Focal gland formation in grade 3 
endometrioid adenocarcinoma may mimic rosettes and tubules of a PNET; however, there is 
extensive keratin expression in high grade endometrioid adenocarcinoma compared to little 
if any staining in PNET. GFAP expression confirms central PNET, but may also rarely be 
seen in Müllerian carcinomas (69). Concurrent diffuse and strong membranous CD99 and 
nuclear Fli-1 expression, immunoreactivity with at least one neuroendocrine marker and no 
or limited keratin staining are also features helpful in distinguishing Ewing sarcoma/
peripheral PNET from undifferentiated and high-grade endometrioid carcinoma. 
Additionally, DNA mismatch repair protein deficiency may favor high-grade endometrioid 
and undifferentiated carcinoma, the latter also sometimes demonstrating loss of BRG1, 
BRM, and INI1 expression (70, 71). Metastatic tumors, such as malignant melanoma, 
lymphoma, small cell carcinoma of pulmonary origin, and round cell sarcomas, may be 
mistaken as PNET; however, clinical history, bilateral adnexal involvement in the setting of 
an ovarian tumor, thorough sampling of the tumor tissue, and immunohistochemistry should 
facilitate the correct diagnosis.
In summary, the vast majority of PNETs arising in the ovary and uterus are of the central 
type, display morphologic features reminiscent of CNS tumors, and lack EWSR1 
rearrangement. Central PNETs may be further subtyped along neuronal, glial, or ependymal 
lines of differentiation. Ewing sarcoma/peripheral PNETs may also be found in the ovary 
and uterus, but tend to predominate in the cervix, vagina, and vulva. Tumors that consist of 
small round blue cells with concurrent strong and diffuse membranous CD99 and nuclear 
Fli-1 staining likely harbor EWSR1 rearrangement. Tumors with the morphology of Ewing 
sarcoma/peripheral PNET morphology, but without EWSR1 rearrangement should remain 
classified as such unless morphologic or immunohistochemical (i.e. GFAP) evidence of CNS 
differentiation is seen. Distinction between central and peripheral types of PNET in the 
female genital tract may be useful in developing treatment strategies for patients with this 
rare tumor type.
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Figure 1. 
Morphology of central PNET with features of medulloblastoma. A–D, Medulloblastoma 
demonstrating nodular growth (A) with pale islands of neuronal differentiation (B, star and 
C) neighboring primitive undifferentiated areas (B, arrow and D).
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Figure 2. 
Morphology of central PNETs with features of medulloepithelioma and glioblastoma. A and 
B, Multilayered rosettes with apical mitoses (B, arrow) typical of medulloepithelioma. C and 
D, Glial differentiation with foci of pseudopalisading necrosis (C) and microvascular 
proliferation (D).
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Figure 3. 
Ewing sarcoma/peripheral PNET. A, Sheets of small round blue cells. B, Strong nuclear 
Fli-1 expression. C, Membranous CD99 staining. D, EWSR1 rearrangement confirmed by 
separation of green and red FISH probe signals flanking the EWSR1 gene.
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Figure 4. 
Immunohistochemical features of central PNET. A, Diffuse, focal, and scattered 
synaptophysin positivity confirming neuronal differentiation in differentiated (top) and 
undifferentiated foci (bottom). B, GFAP expression of scattered glial cells in central PNET. 
C and D, Central PNET with features of ependymoma demonstrating concurrent strong and 
diffuse membranous CD99 (C) and nuclear Fli-1 (D) expression.
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